Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
Cardiovascular Diabetology, 06/08/2012Klempfner R et al.
Demonstrating antiatherothrombotic properties of dipeptidyl peptidase–4 inhibitors on proven markers is of substantial clinical significance. Coupled with their proven good safety profile these findings could translate into a significant clinical benefit.
Authors plan to prospectively investigate the effects of dipeptidyl peptidase–4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes.
The selected markers are: interleukin–6, high sensitivity C reactive protein, interleukin 1–beta, total adiponectin levels, matrix metallo–proteinase 9 and platelet reactivity testing.
Sixty eligible patients will be randomized in a 2:1 ratio to vildagliptin/metformin or metformin only treatment, for a 3–month duration treatment.
Blood sampling for the proposed investigations will be taken at enrollment and immediately after completion of the study period.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.